The company has launched Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the US, following the approval from the USFDA

Lupin Ltd. has an average target of 2336.09 from 11 brokers.

Lupin partners with TB Alliance for clinical development, commercialisation of investigational drug Telacebec

Business Line | 02 Feb 2026

Lupin Ltd.

02 Feb 2026

2173.70

-2.02%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Launches Dasatinib Tablets in the United States.

pdf

Lupin Ltd.

02 Feb 2026

2173.70

-2.02%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Diseases.

pdf

Lupin Ltd.

28 Jan 2026

2173.70

-2.02%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Schedule of Earnings Call for Unaudited Financial Results of Q3 FY26.

pdf

Lupin Ltd.

28 Jan 2026

2173.70

-2.02%

Board Meeting

Lupin Ltd - 500257 - Board Meeting Intimation for Considering And Approving The Unaudited Standalone And …

BSE India

Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025.

pdf

Lupin Ltd.

27 Jan 2026

2173.70

-2.02%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Intimation of allotment of 169140 equity shares under ESOP.

pdf

Lupin Ltd.

23 Jan 2026

2173.70

-2.02%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Receives Highest ESG Rating from CDP for Climate Change and Water Security.

pdf

Lupin Ltd.

21 Jan 2026

2173.70

-2.02%

Lupin signs licensing pact with Galenicum Health for injectable Semaglutide

Business Standard

Drug maker Lupin on Wednesday said its subsidiary, Lupin Atlantis Holdings SA (LAHSA), has inked a licence and supply agreement with Galenicum Health for diabetes and weight management medication. Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing, and supply, while Lupin will handle regulatory submissions, approvals, and the commercialisation and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based drug maker said in a statement. "Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy," said Fabrice Egros, President, Corporate...

Lupin Ltd. has an average target of 2336.09 from 11 brokers.

Lupin inks supply agreement with Galenicum Health for injectable semaglutide

Business Line | 21 Jan 2026

Is Lupin Ltd. worth buying?

935 Votes:

Buy 72.83%

Sell 17.54%

Hold 9.63%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf